GSK-J4: An H3K27 histone demethylase inhibitor, as a potential anti-cancer agent

Area of Science:

• Epigenetics and Molecular Oncology
• Cancer Biology and Therapeutics

Background:

• Aberrant epigenetic modifications, particularly deregulation of H3K27me3 marks, are key drivers in tumor initiation and progression.
• The H3K27me3 mark, associated with gene silencing, represents a targetable mechanism due to its reversible nature in cancer treatment.

Purpose of the Study:

• To review the anti-cancer properties of GSK-J4, a histone demethylase inhibitor targeting JMJD3/UTX.
• To summarize GSK-J4's molecular pathways, in-vivo efficacy, and combination potential in various cancer models.

Main Methods:

• Literature review of studies investigating GSK-J4's anti-cancer effects.
• Analysis of molecular pathways modulated by GSK-J4, including apoptosis, cell cycle, and DNA damage repair.
• Evaluation of in-vivo studies and drug combination strategies involving GSK-J4.

Main Results:

• GSK-J4 effectively targets multiple cancer-related pathways, including apoptosis, cell cycle regulation, invasion, migration, DNA damage repair, metabolism, oxidative stress, and stemness.
• In-vivo studies demonstrate GSK-J4's anti-cancer activity across different cancer models.
• GSK-J4 shows potential for synergistic effects when combined with conventional anti-cancer drugs.

Conclusions:

• GSK-J4 exhibits significant anti-cancer properties by modulating H3K27me3 levels.
• GSK-J4 is a promising therapeutic candidate, both as a monotherapy and in combination regimens, for various cancer types.